**Lake Street Initiates Coverage of Spruce Biosciences with ‘Buy’ Recommendation**
On September 17, 2026, Lake Street initiated coverage of Spruce Biosciences (NASDAQ: SPRB) with a **Buy** rating. Spruce is a late-stage biopharmaceutical company developing novel therapies for rare endocrine disorders. The company’s lead product candidate, tildacerfont, aims to be the first non-steroidal treatment for classic congenital adrenal hyperplasia (CAH) and is also in development for certain cases of polycystic ovary syndrome (PCOS).
As of September 16, 2026, Spruce’s stock closed at $53.36, down from $54.16 the previous day, reflecting a 1.82% decline over the past week and a modest 0.83% increase over the past month. The consensus target price for the stock stands at $150.83, indicating a potential upside of 182.67%. Current analyst sentiment shows 5 strong buy, 8 buy, and 1 hold ratings, yielding a positive recommendation rate of 92.9%.
In its latest earnings report on August 12, 2026, Spruce reported an EPS of -6.68, against an estimate of -5.92, with actual revenue recorded at $0.00. The company’s total liabilities and stockholders’ equity were reported at $102,852 as of June 30, 2026.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
